Nahdi Medical Future Growth
Future criteria checks 3/6
Nahdi Medical is forecast to grow earnings and revenue by 6.1% and 5.9% per annum respectively. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be 31.8% in 3 years.
Key information
6.1%
Earnings growth rate
6.1%
EPS growth rate
Consumer Retailing earnings growth | 19.6% |
Revenue growth rate | 5.9% |
Future return on equity | 31.8% |
Analyst coverage | Good |
Last updated | 09 Dec 2024 |
Recent future growth updates
Recent updates
Returns On Capital Signal Tricky Times Ahead For Nahdi Medical (TADAWUL:4164)
Oct 18Nahdi Medical Company's (TADAWUL:4164) Share Price Is Matching Sentiment Around Its Earnings
Sep 13Nahdi Medical Company Beat Revenue Forecasts By 6.2%: Here's What Analysts Are Forecasting Next
Aug 07Nahdi Medical (TADAWUL:4164) Has Announced A Dividend Of SAR2.50
Aug 03Capital Allocation Trends At Nahdi Medical (TADAWUL:4164) Aren't Ideal
Jun 18There's No Escaping Nahdi Medical Company's (TADAWUL:4164) Muted Earnings
Apr 25Nahdi Medical (TADAWUL:4164) Is Paying Out A Dividend Of SAR3.00
Mar 21The Returns On Capital At Nahdi Medical (TADAWUL:4164) Don't Inspire Confidence
Jan 07Analyst Estimates: Here's What Brokers Think Of Nahdi Medical Company (TADAWUL:4164) After Its First-Quarter Report
Aug 07Here's What's Concerning About Nahdi Medical's (TADAWUL:4164) Returns On Capital
Jul 25Here's What's Concerning About Nahdi Medical's (TADAWUL:4164) Returns On Capital
Mar 22Nahdi Medical Company's (TADAWUL:4164) Price Is Out Of Tune With Earnings
Dec 13We Think Nahdi Medical's (TADAWUL:4164) Profit Is Only A Baseline For What They Can Achieve
Aug 20Are Investors Undervaluing Nahdi Medical Company (TADAWUL:4164) By 27%?
Aug 01Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 10,573 | 940 | 891 | 1,720 | 5 |
12/31/2025 | 9,952 | 883 | 781 | 1,634 | 6 |
12/31/2024 | 9,491 | 840 | 864 | 1,534 | 4 |
9/30/2024 | 9,298 | 833 | 952 | 1,348 | N/A |
6/30/2024 | 9,107 | 864 | 913 | 1,339 | N/A |
3/31/2024 | 8,866 | 881 | 808 | 1,218 | N/A |
12/31/2023 | 8,714 | 893 | 984 | 1,369 | N/A |
9/30/2023 | 8,638 | 850 | 1,315 | 1,647 | N/A |
6/30/2023 | 8,634 | 891 | 1,066 | 1,371 | N/A |
3/31/2023 | 8,642 | 895 | 1,435 | 1,721 | N/A |
12/31/2022 | 8,616 | 888 | 1,393 | 1,668 | N/A |
9/30/2022 | 8,451 | 903 | 1,248 | 1,524 | N/A |
6/30/2022 | 8,334 | 897 | 1,277 | 1,555 | N/A |
3/31/2022 | 8,165 | 855 | 1,117 | 1,391 | N/A |
12/31/2021 | 8,066 | 813 | 1,028 | 1,334 | N/A |
9/30/2021 | 8,079 | 836 | 1,329 | 1,621 | N/A |
6/30/2021 | 8,173 | 682 | 1,428 | 1,721 | N/A |
3/31/2021 | 8,363 | 750 | 1,490 | 1,818 | N/A |
12/31/2020 | 8,642 | 849 | 1,266 | 1,586 | N/A |
12/31/2019 | 7,825 | 692 | 1,114 | 1,348 | N/A |
12/31/2018 | 7,350 | 611 | 797 | 980 | N/A |
12/31/2017 | 7,056 | 721 | N/A | 911 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 4164's forecast earnings growth (6.1% per year) is below the savings rate (14.7%).
Earnings vs Market: 4164's earnings (6.1% per year) are forecast to grow faster than the SA market (5.9% per year).
High Growth Earnings: 4164's earnings are forecast to grow, but not significantly.
Revenue vs Market: 4164's revenue (5.9% per year) is forecast to grow faster than the SA market (-0.6% per year).
High Growth Revenue: 4164's revenue (5.9% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 4164's Return on Equity is forecast to be high in 3 years time (31.8%)
Discover growth companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/22 23:30 |
End of Day Share Price | 2024/12/22 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Nahdi Medical Company is covered by 7 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Duaa AlFadda | BofA Global Research |
Michel Salameh | Citigroup Inc |
Ahmed Moataz | EFG-Hermes Research |